We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

Article   Mar 28, 2017 | Original Article by Adam Tozer Ph.D

 
Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

ADCs are the next generation of cancer therapies. Credit: Lonza

 
 
 

RELATED ARTICLES

Big Data Analysis Approaches for Drug Discovery

Article

Big data has long been a buzzword in drug discovery, but as analysis methods become more sophisticated, its potential is beginning to be realized. We look at some of the latest advances in big data analysis for drug discovery.

READ MORE

Overcoming Challenges in Biopharma: Transformational Innovation is Key

Article

Looking at the industry growth and the complexities of biopharma development, it is no wonder that transformational developments are required to better equip laboratories and operations in biopharma.

READ MORE

Neutrons – A New Weapon Against Cancer

Article

The development of cancer is a complex process, which can result from minor mistakes in an otherwise well-functioning network of cellular processes. As such, it is essential that scientists have a clear picture of biochemical processes at an atomic level in order to gain an in-depth understanding of how various cancers occur and develop. One technique starting to gain recognition as a powerful tool is neutron crystallography.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE